In 2015, Hellenic Cooperative Oncology Group validation study reported that the combination of high EGFR, high HER2, low HER3 and low HER4 mRNA expression was associated with a trend for shorter OS and significantly worse disease-free survival in high-risk early breast cancer patients [37]. The gene discussed is ERBB2; the disease is breast carcinoma.